Dental Biomaterials – Market Insights – Europe

The European dental biomaterial market will grow moderately through 2027, driven by an increasing number of GDs offering dental implant therapy and widespread awareness of dental implant treatments, leading to a greater volume of procedures incorporating dental biomaterials because bone grafting is often performed alongside dental implant placements. Companies in this space are also investing in innovative technologies to expand revenues and gain shares in this market. 

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for dental biomaterials in Europe across a 10-year period.

Stringent regulations surrounding animal and human tissue products have made it difficult for manufacturers to enter and compete in these market segments.

How does the penetration of animal- and human-derived dental biomaterials in Europe differ from the penetration in North America?

What impact does this have on the adoption of these products in comparison to synthetics?

As the market matures, companies are increasingly focusing on innovative technologies to gain a competitive advantage.

What innovations are being developed in the dental biomaterial space?

What are the potential benefits associated with these novel products, and how will it affect the positions of the companies in the market?

Strategic acquisitions, partnerships, and distribution deals help manufacturers expand their product portfolios and customer bases.

Which companies have recently engaged in M&A activity, and how have these deals benefited them?

Which competitors have engaged in distribution relationships, and how are distribution agreements affecting the market?